Quotient Sciences Header

Quotient Sciences Header

X

Find Neurology Drugs in Phase II/III Clinical Development in JAPAN

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka announces positive top-line results from clinical trials in Japan of\\nfremanezumab as a prophylactic treatment for migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Otsuka Pharmaceutical"},{"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subject Enrolled in Phase II\/III Study of Eisai\u2019s Anti-Mtbr Tau Antibody E2814 For Dominantly Inherited Alzheimer's Disease (DIAD), Conducted By DIAN-TU","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Eisai"}]

Eisai

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

First Subject Enrolled in Phase II/III Study of Eisai’s Anti-Mtbr Tau Antibody E2814 For Dominantly Inherited Alzheimer's Disease (DIAD), Conducted By DIAN-TU

Details:

An investigational anti-microtubule binding region (MTBR) tau antibody, E2814 is being developed as a disease modifying agent for tauopathies including sporadic AD. E2814 is designed to prevent the spreading of tau seeds within the brains of affected individuals.

Lead Product(s): E2814,Lecanemab

Therapeutic Area: Neurology Product Name: E2814

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 19, 2022

ASK
US

Upload
your Pipeline Activity

Otsuka Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Otsuka announces positive top-line results from clinical trials in Japan ofnfremanezumab as a prophylactic treatment for migraine

Details:

Preliminary trial results indicated that primary endpoints were achieved with statistical significance versus placebo for subjects with chronic migraine and episodic migraine, respectively.

Lead Product(s): Fremanezumab

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY